Docetaxel/Ritonavir Drug Asset Due Diligence Report 2026

This Docetaxel/Ritonavir Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

2919

Registered trials

2844

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Docetaxel/Ritonavir can convert its Small molecule drug profile and HIV-1 pol x Tubulin biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Docetaxel/Ritonavir (query alias: Docetaxel/Ritonavir)
Modality / target	Small molecule drug; HIV-1 pol x Tubulin; HIV-1 pol inhibitors, Tubulin modulators
Highest global status	Phase 2
Originator	Netherlands Cancer Insitute
Active developers	Modra Pharmaceuticals BV

The MCP disease footprint includes Breast Cancer, Prostatic Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07824869	Phase 2	Not yet recruiting	90	Primary endpoint not disclosed in English source
NCT07805135	Phase 3	Not yet recruiting	430	Primary endpoint not disclosed in English source
NCT07797218	Phase 3	Recruiting	220	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Real-World Survival Outcomes With Tumor Treating Fields Therapy in Advanced Non-Small Cell Lung Cancer: Impact of Treatment Sequencing

Not Applicable; n=16; evaluation: Positive. Reported fields: mOS = 19.9 Month ; mOS = 19.9 Month

ResQ201A: 2L+ Mnsclc ICI Failure: Randomized Phase 3 Trial of NAI + ICI + 2 Cycles Docetaxel vs Docetaxel

Phase 3; n=582; evaluation: Positive. Reported fields: DoR(≥ 6-month) = 9.0 % ; mOS = 9.8 Month ( 9.1 - 10.6)

Real-World Study of Cadonilimab Plus Docetaxel Versus Docetaxel in Advanced NSCLC Progressing on PD-(l)1 Inhibitors

Not Applicable; n=63; evaluation: Positive. Reported fields: mPFS = 7.8 Month ( 6.1 - 9.4); mPFS = 3.6 Month ( 3.0 - 4.3)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Docetaxel/Ritonavir addresses Breast Cancer, Prostatic Cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 6 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-09-30	Boryung completes Sanofi Taxotere takeover, launches global oncology biz	Approved	US$16.0M milestones; US$205.0M stated total
2025-02-18	Transaction title not available in English source	Approved	US$25.0M upfront
2022-02-18	MGH and Orion will collaborate on a study involving the combination of darolutamide/placebo, androgen-deprivation therapy, and docetaxel for the treatment of metastatic, hormone-sensitive prostate cancer.	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods and compositions for treating cancer in taxane-resistant patients”. The milestone feed surfaced a patent-application signal described as “Cancer treatment using docetaxel by controlling peak plasma levels”. The milestone feed surfaced a patent-application signal described as “Combination treatment for solid tumors using docetaxel and a CYP3a inhibitor”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO